Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 1/20 | 0.44 |
| ▸ | KDR | P35968 | 3/20 | 0.41 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.39 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.39 |
| ▸ | CDK2 | P24941 | 1/20 | 0.39 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.39 |
| ▸ | EGFR | P00533 | 9/20 | 0.39 |
| ▸ | FLT1 | P17948 | 1/20 | 0.38 |
| ▸ | SYK | P43405 | 1/20 | 0.38 |
| ▸ | JAK2 | O60674 | 1/20 | 0.38 |
| ▸ | JAK1 | P23458 | 1/20 | 0.38 |
| ▸ | FBP1 | P09467 | 1/20 | 0.37 |
| ▸ | CNR2 | P34972 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6479294 | 0.85 | CYP19A1 (0.48) | CYP19A1KDRCCNA2CDK2CCNA1 | |
| SCHEMBL14214693 | 0.79 | FGFR2 (0.42) | CYP19A1KDRCCNA2CDK2CCNA1 | |
| SCHEMBL31286290 | 0.79 | CYP19A1 (0.64) | CYP19A1 | |
| SCHEMBL16100647 | 0.79 | CYP19A1 (0.64) | CYP19A1 | |
| SCHEMBL6478557 | 0.76 | PIK3CA (0.47) | CYP19A1KDRCDK2 | |
| SCHEMBL6479012 | 0.76 | PIK3CA (0.47) | CYP19A1KDRJAK2JAK1 | |
| SCHEMBL14214606 | 0.75 | KDR (0.47) | KDRPDGFRBCCNA2CDK2CCNA1 | |
| SCHEMBL6491499 | 0.73 | SYK (0.51) | KDRCDK2EGFRSYKCNR2 | |
| SCHEMBL14214697 | 0.72 | CCNT1 (0.42) | CCNA2CDK2CCNA1 | |
| SCHEMBL6490195 | 0.72 | KDR (0.40) | KDRCDK2EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6864255-B2 | Substituted triazinyl amide derivatives and methods of use | AMGEN INC. (US) | 2005-03-08 | — | — | US | disclosed |
| US-20030087908-A1 | Substituted triazinyl amide derivatives and methods of use | AMGEN INC. | 2003-05-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030087908-A1 | Substituted triazinyl amide derivatives and methods of use | FLT4, FLT1, VEGFA | CYP19A1 215/4885KDR 4/4885PDGFRB 26/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.